

## Curriculum Vitae

Prof. Karl-Heinz Altmann  
ETH Zürich  
Department of Chemistry and Applied Biosciences  
Institute of Pharmaceutical Sciences  
ETH Hönggerberg HCI H 405  
Vladimir-Prelog-Weg 4  
CH-8093 Zürich, Switzerland  
Phone: +41 (0)44 633 73 90  
FAX: +41 (0)44-633 13 60  
[karl-heinz.altmann@pharma.ethz.ch](mailto:karl-heinz.altmann@pharma.ethz.ch)

Date of Birth: June 20, 1957.  
Place of Birth: Hochheim/Main, Germany.  
Citizenship: Germany and Switzerland  
Marital Status: Married to Eva Altmann-Schaffner since March 7, 1986.  
1 Daughter, Sandrine Katharina, born May 8, 1993.  
1 Son, Christoph Manuel, born July 24, 1996.

### **Educational Record**

April 1964 - June 1967: Elementary School.  
Sept. 1967 - May 1976: High school (Gymnasium).  
May 1976: Abitur.  
Oct. 1976 - May 1982: Undergraduate studies in chemistry at the Johannes-Gutenberg Universität, Mainz, Germany (interrupted between April 1977 and March 1978 to perform mandatory civil service).  
May/June 1982: Oral diploma exam in chemistry.  
Aug. 1982 - May 1983: Diploma thesis in chemistry with Prof. Manfred Mutter entitled: "Synthesis und Conformational Studies on Host-Guest peptides and on Thermolysin 75 - 84".  
May 1983 - Feb. 1984: PhD work with Prof. Manfred Mutter at the Johannes-Gutenberg Universität, Mainz, Germany.  
Feb. 1984: Move to Basel, Switzerland and continuation of PhD work at the Institute of Organic Chemistry, University of Basel (Prof. Manfred Mutter).  
Sept. 1984 - July 1985: Teaching assistant: Organic chemistry lab course for students of biology and pharmacy.  
Aug. 1985 - Feb. 1987: Teaching assistant: Organic chemistry lab course for students of chemistry.  
Dec. 1986: PhD exam passed with "summa cum laude" (Dr. phil. II).

Title of PhD thesis: "Design, Synthesis, and Conformational Studies of Polypeptides with  $\beta\alpha\beta$ -Folding Topology".

Feb. 1987 - Aug. 1989: Postdoctoral studies with Prof. Harold Scheraga at the Department of Chemistry, Cornell University, Ithaca, New York, USA.

Sept. 1989 - Aug. 1990: Assistant Professor at the Institute of Organic Chemistry, University of Lausanne.

### Professional Career

Sept. 1990: Start as a research scientist at the Central Research Laboratories (CRL) of Ciba-Geigy AG, Basel.

Sept. 1992: Project leader (Section "Nucleic Acid Chemistry").

Jan. 1995: Project and group leader (Section "Nucleic Acid Chemistry"): Project "Modified antisense oligonucleotides" (building block design and synthesis).

Responsible for project collaboration with ISIS Pharmaceuticals, Carlsbad CA, and Ciba Central Research Laboratories in Macclesfield, UK.

CRL representative in the joint ISIS/Ciba project team which moved antisense oligonucleotides ISIS 5132 and 3521 to Phase I clinical trial (cancer indication).

June 1996: In addition to above responsibilities head of Central Oligonucleotide Synthesis Lab within CRL. Vice section head.

Jan. 1997 - Oct. 2000: Due to the dissolution of Ciba CRL as a consequence of the merger between Sandoz AG and Ciba-Geigy AG to form Novartis, move to "Therapeutic Area Oncology" within Novartis Pharma Research. Program Team Head for the "Epothilone Program".

As research member of the corresponding development teams ("Compound Profiling Team" at the earlier stages of preclinical development, later "International Project Team") central driving force for the progression of epothilone B (EPO906, patupilone) to Phase I clinical trials (cancer indication).

Nov. 2000 - Dec. 2002: Novartis Pharma Senior Chemistry Expert.

Head of the Scientific Chemistry Council.

Member of the Global Research Management Board of Novartis Pharma.

Jan. 2003 - June 2003: Global Head of Chemistry *ad interim*, Novartis Institutes of Biomedical Research.

July 2003 – current: Professor of Pharmaceutical Sciences at the Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zürich.

July 2007 – Nov. 2014: Director of Studies ("Studiendelegierter):

- BSc/MSc programs in Pharmaceutical Sciences.  
MSc program in Medicinal and Industrial Pharmaceutical Sciences.
- Aug. 2015 – July 2016: Deputy Department Head, Department of Chemistry and Applied Biosciences, ETH Zürich
- Aug. 2016 – July 2018: Department Head, Department of Chemistry and Applied Biosciences, ETH Zürich  
Director Studies, BSc/MSc programs in Chemistry
- Aug. 2018 – July 2019: Deputy Department Head, Department of Chemistry and Applied Biosciences, ETH Zürich

### **Awards**

- December 1998 Novartis Leading Scientist Award.
- November 2004 Novartis Lecturer for Central Europe.
- July 2015 Paul Ehrlich Award of the Société Chimie Thérapeutique, France.

### **Board Membership**

Swiss Chemical Society (SCS) (2011-2013)

Division of Medicinal Chemistry and Chemical Biology of the SCS (2000-current; president from 2011-2013)

### **Scientific Advisory Boards:**

*Evolva AG*, Reinach, Switzerland

*Global Antibiotic Research & Development Partnership (GARDP)*, Geneva, Switzerland

*Helmholtz Institute of Pharmaceutical Sciences*, Saarbrücken, Germany

*Institute of Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB)*, Prague, Czech Republic

*Leibniz Institute of Molecular Pharmacology*, Berlin, Germany

*Nextech Venture Ltd.*, Zürich, Switzerland

*Novartis Institute for Tropical Diseases (NITD)*, Singapore (Chair) (2007-2016)

*Bioorganic & Medicinal Chemistry (Letters)* (2005-2013)

*ChemBioChem* (2004-2010)

*Chimia*

*Helvetica Chimica Acta* (1997-2016)

*Journal of Medicinal Chemistry*

Member of the Editorial Board of *ChemMedChem*

## **Editing**

Co-editor of a book on *Anticancer Agents – Frontiers in Cancer Chemotherapy*, Ojima, I.; Vite G. D.; Altmann, K.-H., Eds., ACS Symposium Series 796, American Chemical Society, Washington DC, 2001.

Co-guest editor (with Prof. Dario Neri, ETH Zürich): *Curr. Opin. Chem. Biol.* **2009**, *13*. Issue on *Next generation therapeutics*.

Guest editor: *Bioorg. Med. Chem.* **2014**, *22*. Symposium-in-Print on *The cytoskeleton and its interactions with small molecules*.

## **Companies**

Co-founder of Tolremo Therapeutics AG (2017)